Modality
Multispecific
MOA
CD47i
Target
FcRn
Pathway
PI3K/AKT
UCGISTCML
Development Pipeline
Preclinical
~May 2012
→ ~Aug 2013
Phase 1
~Nov 2013
→ ~Feb 2015
Phase 2
~May 2015
→ ~Aug 2016
Phase 3
~Nov 2016
→ ~Feb 2018
NDA/BLA
May 2018
→ Sep 2031
NDA/BLACurrent
NCT07781952
2,281 pts·UC
2018-05→2030-05·Completed
NCT07683401
906 pts·CML
2020-04→2031-09·Active
3,187 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-05-074.1y awayPh3 Readout· UC
2031-09-285.5y awayPh3 Readout· CML
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Complet…
NDA/BLA
Active
Catalysts
Ph3 Readout
2030-05-07 · 4.1y away
UC
Ph3 Readout
2031-09-28 · 5.5y away
CML
ActiveCompleted|StartCompletionToday
Trials (2)
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Sovafutibatinib | Moderna | Approved | FcRn |